03:52 AM EST, 01/23/2025 (MT Newswires) -- Exicure ( XCUR ) said late Wednesday it has agreed to acquire all shares of GPCR Therapeutics USA, a subsidiary of GPCR Therapeutics, a Korean corporation.

In connection with the deal, Exicure ( XCUR ) and GPCR made a licensing and collaboration agreement to further develop and commercialize certain GPCR technologies, the company said.

Financial terms were not disclosed.

Under the agreement, Exicure ( XCUR ) is to pay GPCR milestone payments upon reaching specific milestone events relating to clinical trials, marketing authorizations, and net sales, as well as a recurring royalty payment based on at least 10% of net sales, the company said.

Shares of Exicure ( XCUR ) were up more than 46% in Wednesday's after-hours activity.

Price: 15.21, Change: +4.84, Percent Change: +46.67